Perceptive Advisors LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Perceptive Advisors LLC reported 99 stock positions worth $6.4 billion. Its top holding was Praxis Precision Medicines I (PRAX) at 10.6% of the portfolio, followed by Spyre Therapeutics (SYRE, 6.0%) and Celcuity (CELC, 5.2%). Compared with Q1 2026, it opened 21 new positions, sold out of 11, added to 30 and reduced 28. The biggest buy was a new position in Kardigan (KARD) and the biggest sale an exit from Centessa Pharmaceuticals (CNTA).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001224962
- Portfolio Value
- $6.4B (Q2 2026)
- SEC Filing
- 0001012975-26-000777 ↗ filed Aug 14, 2026
Holdings Value
Holdings 99 stocks · $6.4B
| PRAX Praxis Precision Medicines I | 10.61% | 2,035,986 | $681.6M | No change |
| SYRE Spyre Therapeutics Inc. | 5.97% | 4,319,496 | $383.5M | Add +14.2% |
| CELC Celcuity Inc. | 5.21% | 3,197,200 | $334.5M | Add +2.2% |
| ASND Ascendis Pharma A/S | 4.83% | 1,163,721 | $310.4M | Reduce -24.0% |
| RYTM Rhythm Pharmaceuticals Inc. | 4.47% | 2,586,295 | $287.2M | Add +8.9% |
| ROIV Roivant Sciences Ltd. | 4.45% | 8,085,461 | $286.1M | Reduce -2.4% |
| RLAY Relay Therapeutics Inc. | 4.11% | 14,106,187 | $263.9M | Add +44.7% |
| TVTX Travere Therapeutics Inc. | 3.32% | 3,752,574 | $213.2M | Reduce -9.4% |
| KARD Kardigan Inc. | 3.04% | 8,200,662 | $195.6M | New |
| NUVL Nuvalent Inc. Class A | 3.04% | 1,580,505 | $195.2M | No change |
| EWTX Edgewise Therapeutics Inc. | 2.77% | 4,373,974 | $177.7M | Reduce -1.1% |
| APGE Apogee Therapeutics Inc. | 2.70% | 1,308,113 | $173.6M | Reduce -15.1% |
| AMLX Amylyx Pharmaceuticals Inc. | 2.33% | 8,334,882 | $149.7M | Add +0.6% |
| MGTX Meiragtx Holdings PLC | 2.27% | 10,786,658 | $145.7M | Add +4.5% |
| ORKA Oruka Therapeutics Inc. | 1.99% | 1,345,063 | $128.0M | Reduce -3.6% |
| INBX Inhibrx Biosciences Inc. | 1.91% | 1,297,763 | $123.0M | Reduce -10.1% |
| PTGX Protagonist Therapeutics Inc. | 1.87% | 981,879 | $120.4M | Reduce -20.2% |
| SLDB Solid Biosciences Inc. | 1.85% | 11,906,646 | $118.9M | No change |
| ZYME Zymeworks Inc. | 1.70% | 4,182,953 | $109.3M | Add +19.2% |
| TNGX Tango Therapeutics Inc. | 1.64% | 3,377,000 | $105.6M | Add +317.9% |
| IMTX Immatics NV | 1.64% | 10,383,456 | $105.2M | No change |
| NRIX Nurix Therapeutics Inc. | 1.63% | 4,320,422 | $104.8M | Add +16.4% |
| BCRX Biocryst Pharmaceuticals Inc. | 1.60% | 10,308,888 | $103.1M | Add +38.7% |
| RVMD Revolution Medicines Inc. | 1.54% | 527,600 | $98.8M | Add +104.0% |
| AVLN Avalyn Pharma Inc. | 1.37% | 2,675,296 | $88.1M | New |
| DYN Dyne Therapeutics Inc. | 0.93% | 2,689,235 | $59.7M | Reduce -42.4% |
| BIIB Biogen Inc. | 0.93% | 276,173 | $59.7M | New |
| IMVT Immunovant Inc. | 0.81% | 1,357,383 | $52.3M | Reduce -15.0% |
| UNH Unitedhealth Group Inc. | 0.76% | 116,806 | $48.5M | New |
| IONS Ionis Pharmaceuticals Inc. | 0.70% | 566,000 | $44.9M | Add +12.3% |
| STRO Sutro Biopharma Inc. | 0.67% | 1,304,846 | $43.3M | Add +82.4% |
| ANRO Alto Neuroscience Inc. | 0.66% | 1,609,893 | $42.5M | Reduce -19.9% |
| JAZZ Jazz Pharmaceuticals PLC | 0.64% | 170,000 | $41.0M | No change |
| CRVS Corvus Pharmaceuticals Inc. | 0.62% | 2,667,441 | $39.9M | Add +16.4% |
| SION Sionna Therapeutics Inc. | 0.62% | 905,000 | $39.8M | Add +37.5% |
| CTMX Cytomx Therapeutics Inc. | 0.61% | 10,439,185 | $39.1M | Add +3.4% |
| AORT Artivion Inc. | 0.61% | 1,737,290 | $39.0M | Add +6.1% |
| XFOR X4 Pharmaceuticals Inc. | 0.58% | 7,933,491 | $37.0M | Add +17.8% |
| CORT Corcept Therapeutics Inc. | 0.54% | 398,385 | $34.6M | Add +696.8% |
| RGEN Repligen Corp. | 0.53% | 248,212 | $33.9M | Reduce -11.5% |
| AVR Anteris Technologies Global | 0.53% | 3,425,476 | $33.7M | No change |
| RAPP Rapport Therapeutics Inc. | 0.50% | 773,342 | $32.2M | Add +14.8% |
| DMRA Damora Therapeutics Inc. | 0.50% | 1,223,000 | $31.8M | No change |
| CRL Charles River Laboratories | 0.49% | 140,000 | $31.8M | New |
| AXSM Axsome Therapeutics Inc. | 0.45% | 118,450 | $29.0M | Reduce -21.0% |
| DBVT DBV Technologies SA-Spon ADR | 0.42% | 1,653,350 | $27.1M | Add +71.4% |
| IRTC Irhythm Holdings Inc. | 0.41% | 223,766 | $26.6M | Add +113.1% |
| ADPT Adaptive Biotechnologies | 0.41% | 1,217,325 | $26.1M | Add +698.3% |
| SABS Sab Biotherapeutics Inc. | 0.40% | 6,627,501 | $25.8M | Add +3.0% |
| DHR Danaher Corp. | 0.39% | 130,000 | $24.8M | New |
| TENX Tenax Therapeutics Inc. | 0.39% | 1,700,000 | $24.7M | Add +17.4% |
| NAUT Nautilus Biotechnology Inc. | 0.34% | 11,634,211 | $21.8M | Reduce -7.6% |
| OBIO Orchestra Biomed Holdings Inc. | 0.34% | 5,037,906 | $21.7M | No change |
| ISRG Intuitive Surgical Inc. | 0.32% | 51,884 | $20.6M | Reduce -39.3% |
| ANL Adlai Nortye Group Ltd. | 0.32% | 1,793,190 | $20.6M | New |
| CTNM Contineum Therapeutics Inc. Class A | 0.32% | 1,255,592 | $20.6M | No change |
| NVCT Nuvectis Pharma Inc. | 0.29% | 1,000,000 | $18.4M | New |
| PALI Palisade Bio Inc. | 0.27% | 8,425,065 | $17.6M | Reduce -5.6% |
| OMDA Omada Health Inc. | 0.27% | 786,330 | $17.3M | No change |
| LONA Leonabio Inc. | 0.27% | 1,859,322 | $17.1M | No change |
| EOLS Evolus Inc. | 0.27% | 2,459,285 | $17.1M | Add +91.1% |
| IVVD Invivyd Inc. | 0.25% | 18,490,636 | $16.1M | Reduce -11.4% |
| MIRM Mirum Pharmaceuticals Inc. | 0.21% | 115,391 | $13.5M | New |
| SRZN Surrozen Inc. | 0.20% | 503,985 | $13.1M | Add +119.7% |
| BBNX Beta Bionics Inc. | 0.20% | 832,944 | $13.1M | Reduce -1.2% |
| AXGN Axogen Inc. | 0.18% | 247,312 | $11.4M | Reduce -64.5% |
| OSCR Oscar Health Inc. Class A | 0.18% | 400,000 | $11.4M | New |
| OCS Oculis Holding AG | 0.17% | 808,827 | $11.2M | Add +63.8% |
| SPTX Seaport Therapeutics Inc. | 0.17% | 500,000 | $10.9M | New |
| VRDN Viridian Therapeutics Inc. | 0.17% | 581,980 | $10.7M | Reduce -50.3% |
| BSX Boston Scientific Corp. | 0.17% | 250,000 | $10.7M | New |
| BLLN Billiontoone Inc. Class A | 0.16% | 86,812 | $10.4M | Reduce -5.5% |
| ABVX Abivax SA-ADR | 0.15% | 74,000 | $9.9M | Reduce -77.5% |
| NTRA Natera Inc. | 0.15% | 34,689 | $9.4M | New |
| ENGN Engene Therapeutics Inc. | 0.13% | 4,822,169 | $8.3M | Reduce -17.3% |
| RACC Research Alliance Corp. Class A | 0.12% | 750,000 | $8.0M | New |
| AGMB Agomab Therapeutics NV | 0.12% | 600,000 | $7.8M | No change |
| CGEM Cullinan Therapeutics Inc. | 0.12% | 426,478 | $7.8M | New |
| QURE Uniqure NV | 0.12% | 168,000 | $7.7M | New |
| MOBI Mobia Medical Inc. | 0.11% | 523,654 | $7.0M | New |
| ADGM Adagio Medical Holdings Inc. | 0.10% | 9,876,586 | $6.4M | Add +0.0% |
| GH Guardant Health Inc. | 0.10% | 41,327 | $6.2M | Reduce -86.2% |
| PHAT Phathom Pharmaceuticals Inc. | 0.09% | 532,000 | $5.8M | Reduce -42.5% |
| OTLK Outlook Therapeutics Inc. | 0.08% | 3,139,216 | $5.0M | New |
| COGT Cogent Biosciences Inc. | 0.07% | 121,082 | $4.7M | No change |
| EDSA Edesa Biotech Inc. | 0.07% | 563,239 | $4.6M | No change |
| AVTX Avalo Therapeutics Inc. | 0.06% | 219,813 | $4.1M | Add +57.4% |
| TWST Twist Bioscience Corp. | 0.06% | 36,812 | $3.8M | Reduce -75.5% |
| CBIO Crescent Biopharma Inc. | 0.06% | 206,942 | $3.7M | No change |
| XERS Xeris Biopharma Holdings Inc. | 0.06% | 467,013 | $3.7M | New |
| OM Outset Medical Inc. | 0.06% | 833,333 | $3.6M | No change |
| BDSX Biodesix Inc. | 0.04% | 108,694 | $2.5M | New |
| CNTB Connect Biopharma Holdings L | 0.03% | 792,696 | $1.9M | No change |
| KPRX Kiora Pharmaceuticals Inc. | 0.02% | 438,471 | $1.2M | New |
| MDLN Medline Inc. Class A | 0.02% | 28,000 | $1.1M | No change |
| ADMA Adma Biologics Inc. | 0.01% | 113,765 | $952K | Reduce -75.7% |
| CPIX Cumberland Pharmaceuticals | 0.01% | 96,982 | $628K | Reduce -50.8% |
| XGN Exagen Inc. | 0.01% | 114,893 | $534K | No change |
| ENSC Ensysce Biosciences Inc. | 0.00% | 86,666 | $25K | No change |
Options reported separately and not counted above: MRNA puts ($70.0M), XBI puts ($47.5M), EYPT puts ($28.6M), CAPR calls ($24.1M), SLS puts ($22.1M), NAMS puts ($16.9M), CAPR puts ($12.0M).
Other holdings (3): bonds, preferreds, convertibles and warrants · $17.0M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| CELCUITY INC (CELC 2.75 08/01/31) | NOTE 2.750% 8/0 · principal | 6,500,000 | $14.6M | No change |
| RVMDW Revolution Medicines Inc.-28 | *W EXP 12/17/202 | 250,000 | $2.3M | No change |
| SRZNW Surrozen Inc.-CW25 | *W EXP 08/01/203 | 166,666 | $3K | No change |
Total filed on the 13F, all lines: $6.4B.
Portfolio Sells Q1 2026 → Q2 2026
| CNTA Centessa Pharmaceuticals Ltd. | Sold out | 0.00% | −4.14 |
| ASND Ascendis Pharma A/S | Reduce -24.0% | 4.83% | −2.11 |
| DYN Dyne Therapeutics Inc. | Reduce -42.4% | 0.93% | −0.75 |
| DAWN Day One Biopharmaceuticals I | Sold out | 0.00% | −0.75 |
| PTGX Protagonist Therapeutics Inc. | Reduce -20.2% | 1.87% | −0.70 |
| ENGN Engene Therapeutics Inc. | Reduce -17.3% | 0.13% | −0.66 |
| NAUT Nautilus Biotechnology Inc. | Reduce -7.6% | 0.34% | −0.63 |
| ABVX Abivax SA-ADR | Reduce -77.5% | 0.15% | −0.57 |
| DRUG Bright Minds Biosciences Inc. | Sold out | 0.00% | −0.55 |
| BLTE Belite Bio Inc. - ADR | Sold out | 0.00% | −0.48 |
| ISRG Intuitive Surgical Inc. | Reduce -39.3% | 0.32% | −0.46 |
| GH Guardant Health Inc. | Reduce -86.2% | 0.10% | −0.45 |
| VRDN Viridian Therapeutics Inc. | Reduce -50.3% | 0.17% | −0.29 |
| IVVD Invivyd Inc. | Reduce -11.4% | 0.25% | −0.29 |
| AXGN Axogen Inc. | Reduce -64.5% | 0.18% | −0.28 |
| ANRO Alto Neuroscience Inc. | Reduce -19.9% | 0.66% | −0.23 |
| EVMN Evommune Inc. | Sold out | 0.00% | −0.20 |
| NMRA Neumora Therapeutics Inc. | Sold out | 0.00% | −0.20 |
| NBIX Neurocrine Biosciences Inc. | Sold out | 0.00% | −0.17 |
| IRD Opus Genetics Inc. | Sold out | 0.00% | −0.17 |
| RGEN Repligen Corp. | Reduce -11.5% | 0.53% | −0.13 |
| PHAT Phathom Pharmaceuticals Inc. | Reduce -42.5% | 0.09% | −0.11 |
| ROIV Roivant Sciences Ltd. | Reduce -2.4% | 4.45% | −0.09 |
| TWST Twist Bioscience Corp. | Reduce -75.5% | 0.06% | −0.08 |
| IKT Inhibikase Therapeutics Inc. | Sold out | 0.00% | −0.08 |
| ADMA Adma Biologics Inc. | Reduce -75.7% | 0.01% | −0.07 |
| APLS Apellis Pharmaceuticals Inc. | Sold out | 0.00% | −0.06 |
| AXSM Axsome Therapeutics Inc. | Reduce -21.0% | 0.45% | −0.05 |
| PALI Palisade Bio Inc. | Reduce -5.6% | 0.27% | −0.04 |
| PTN Palatin Technologies Inc. | Sold out | 0.00% | −0.02 |
| INBX Inhibrx Biosciences Inc. | Reduce -10.1% | 1.91% | −0.01 |
| CPIX Cumberland Pharmaceuticals | Reduce -50.8% | 0.01% | −0.00 |
| EWTX Edgewise Therapeutics Inc. | Reduce -1.1% | 2.77% | +0.01 |
| BLLN Billiontoone Inc. Class A | Reduce -5.5% | 0.16% | +0.02 |
| IMVT Immunovant Inc. | Reduce -15.0% | 0.81% | +0.03 |
| BBNX Beta Bionics Inc. | Reduce -1.2% | 0.20% | +0.04 |
| APGE Apogee Therapeutics Inc. | Reduce -15.1% | 2.70% | +0.13 |
| ORKA Oruka Therapeutics Inc. | Reduce -3.6% | 1.99% | +0.64 |
| TVTX Travere Therapeutics Inc. | Reduce -9.4% | 3.32% | +0.88 |
Portfolio Buys Q1 2026 → Q2 2026
| KARD Kardigan Inc. | New | 3.04% | +3.04 |
| SYRE Spyre Therapeutics Inc. | Add +14.2% | 5.97% | +2.19 |
| RLAY Relay Therapeutics Inc. | Add +44.7% | 4.11% | +2.19 |
| AVLN Avalyn Pharma Inc. | New | 1.37% | +1.37 |
| TNGX Tango Therapeutics Inc. | Add +317.9% | 1.64% | +1.31 |
| RVMD Revolution Medicines Inc. | Add +104.0% | 1.54% | +1.04 |
| BIIB Biogen Inc. | New | 0.93% | +0.93 |
| UNH Unitedhealth Group Inc. | New | 0.76% | +0.76 |
| CORT Corcept Therapeutics Inc. | Add +696.8% | 0.54% | +0.50 |
| MGTX Meiragtx Holdings PLC | Add +4.5% | 2.27% | +0.50 |
| CRL Charles River Laboratories | New | 0.49% | +0.49 |
| NRIX Nurix Therapeutics Inc. | Add +16.4% | 1.63% | +0.49 |
| DHR Danaher Corp. | New | 0.39% | +0.39 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +8.9% | 4.47% | +0.38 |
| ADPT Adaptive Biotechnologies | Add +698.3% | 0.41% | +0.36 |
| STRO Sutro Biopharma Inc. | Add +82.4% | 0.67% | +0.32 |
| ANL Adlai Nortye Group Ltd. | New | 0.32% | +0.32 |
| NVCT Nuvectis Pharma Inc. | New | 0.29% | +0.29 |
| MIRM Mirum Pharmaceuticals Inc. | New | 0.21% | +0.21 |
| BCRX Biocryst Pharmaceuticals Inc. | Add +38.7% | 1.60% | +0.20 |
| OSCR Oscar Health Inc. Class A | New | 0.18% | +0.18 |
| SPTX Seaport Therapeutics Inc. | New | 0.17% | +0.17 |
| IRTC Irhythm Holdings Inc. | Add +113.1% | 0.41% | +0.17 |
| BSX Boston Scientific Corp. | New | 0.17% | +0.17 |
| EOLS Evolus Inc. | Add +91.1% | 0.27% | +0.16 |
| NTRA Natera Inc. | New | 0.15% | +0.15 |
| RACC Research Alliance Corp. Class A | New | 0.12% | +0.12 |
| CGEM Cullinan Therapeutics Inc. | New | 0.12% | +0.12 |
| QURE Uniqure NV | New | 0.12% | +0.12 |
| MOBI Mobia Medical Inc. | New | 0.11% | +0.11 |
| SION Sionna Therapeutics Inc. | Add +37.5% | 0.62% | +0.10 |
| RAPP Rapport Therapeutics Inc. | Add +14.8% | 0.50% | +0.08 |
| OTLK Outlook Therapeutics Inc. | New | 0.08% | +0.08 |
| SRZN Surrozen Inc. | Add +119.7% | 0.20% | +0.07 |
| XERS Xeris Biopharma Holdings Inc. | New | 0.06% | +0.06 |
| AMLX Amylyx Pharmaceuticals Inc. | Add +0.6% | 2.33% | +0.05 |
| BDSX Biodesix Inc. | New | 0.04% | +0.04 |
| XFOR X4 Pharmaceuticals Inc. | Add +17.8% | 0.58% | +0.03 |
| DBVT DBV Technologies SA-Spon ADR | Add +71.4% | 0.42% | +0.02 |
| AVTX Avalo Therapeutics Inc. | Add +57.4% | 0.06% | +0.02 |
| KPRX Kiora Pharmaceuticals Inc. | New | 0.02% | +0.02 |
| ZYME Zymeworks Inc. | Add +19.2% | 1.70% | −0.04 |
| CRVS Corvus Pharmaceuticals Inc. | Add +16.4% | 0.62% | −0.04 |
| IONS Ionis Pharmaceuticals Inc. | Add +12.3% | 0.70% | −0.05 |
| TENX Tenax Therapeutics Inc. | Add +17.4% | 0.39% | −0.07 |
| OCS Oculis Holding AG | Add +63.8% | 0.17% | −0.09 |
| SABS Sab Biotherapeutics Inc. | Add +3.0% | 0.40% | −0.09 |
| ADGM Adagio Medical Holdings Inc. | Add +0.0% | 0.10% | −0.12 |
| CTMX Cytomx Therapeutics Inc. | Add +3.4% | 0.61% | −0.33 |
| AORT Artivion Inc. | Add +6.1% | 0.61% | −0.58 |
Options Activity Q1 2026 → Q2 2026
| XBI SS SPDR S&P Biotech ETF | put | New | 300,000 | $47.5M |
| EYPT Eyepoint Inc. | put | New | 2,000,000 | $28.6M |
| CAPR Capricor Therapeutics Inc. | call | New | 1,000,000 | $24.1M |
| SLS Sellas Life Sciences Group I | put | New | 1,500,000 | $22.1M |
| NAMS Newamsterdam Pharma Co. NV | put | New | 500,000 | $16.9M |
| CAPR Capricor Therapeutics Inc. | put | New | 500,000 | $12.0M |
| OCUL Ocular Therapeutix Inc. | call | Sold out | 500,000 | $4.2Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 99 | $6.4B | PRAX, SYRE, CELC, ASND, RYTM |
| Q1 2026Amended | 89 | $5.0B | PRAX, CELC, ASND, ROIV, CNTA |
| Q4 2025 | 109 | $5.4B | PRAX, CELC, RYTM, ASND, APGE |
| Q3 2025 | 88 | $3.4B | RYTM, ASND, ACLX, CELC, NUVL |
| Q2 2025 | 80 | $2.7B | VRNA, ASND, ACLX, RYTM, NUVL |
| Q1 2025Amended | 84 | $2.8B | VRNA, ACLX, FOLD, EWTX, RYTM |
| Q4 2024 | 95 | $3.6B | VRNA, ACLX, FOLD, RYTM, NUVL |
| Q3 2024 | 99 | $4.7B | ACLX, NUVL, FOLD, IOVA, PCVX |
| Q2 2024Amended | 104 | $4.1B | CERE, FOLD, ACLX, IOVA, NUVL |
| Q1 2024Amended | 102 | $5.7B | CERE, FOLD, IOVA, ACLX, NUVL |